Involvement of the first transmembrane segment of human α 2-adrenoceptors in the subtype-selective binding of chlorpromazine, spiperone and spiroxatrine

British Journal of Pharmacology

Volumn 164, Issue 5, 2011, Pages 1558-1572

  Laurila, J M M ^a   Wissel, G ^b,c   Xhaard, H ^c   Ruuskanen, J O ^a,d   Johnson, M S ^b   Scheinin, M ^a,d  

^a UNIVERSITY OF TURKU   (Finland)

^b ÅBO AKADEMI UNIVERSITY   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

2 adrenoceptor; antagonist docking; first transmembrane domain; G protein coupled receptor; ligand binding; molecular modelling

Indexed keywords

2 [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] 4,4 DIMETHYL 1,3(2H,4H) ISOQUINOLINEDIONE; ALPHA 2A ADRENERGIC RECEPTOR; ALPHA 2B ADRENERGIC RECEPTOR; ALPHA 2C ADRENERGIC RECEPTOR; ATIPAMEZOLE; CHLORPROMAZINE; CLOZAPINE; IDAZOXAN; PRAZOSIN; RAUWOLSCINE; SPIPERONE; SPIROXATRINE;

AMINO TERMINAL SEQUENCE; ARTICLE; CHIMERA; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; EXTRACELLULAR SPACE; LIGAND BINDING; MEMBRANE DOMAIN 1; MOLECULAR DOCKING; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

ADRENERGIC ALPHA-2 RECEPTOR ANTAGONISTS; AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; BINDING, COMPETITIVE; CELL CULTURE TECHNIQUES; CHLORPROMAZINE; CHO CELLS; CRICETINAE; CRICETULUS; DIOXANES; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; RECEPTORS, ADRENERGIC, ALPHA-2; SEQUENCE ALIGNMENT; SPIPERONE; SPIRO COMPOUNDS; TRANSFECTION;

EID: 80054027519     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01520.x     Document Type: Article

References (57)

1. Altman JD, Trendelenburg AU, MacMillan L, Bernstein D, Limbird L, Starke K, et al,. (1999). Abnormal regulation of the sympathetic nervous system in alpha2A-adrenergic receptor knockout mice. Mol Pharmacol 56: 154-161. (Pubitemid 29309824)
2. Ballesteros JA, Weinstein H, (1995). Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. In:, Sealfon SC, (ed.). Receptor Molecular Biology. Academic Press Inc: San Diego, CA, pp. 366-427.
3. Boeckler F, Lanig H, Gmeiner P, (2005). Modeling the similarity and divergence of dopamine D2-like receptors and identification of validated ligand-receptor complexes. J Med Chem 48: 694-709. (Pubitemid 40209092)
4. Bokoch MP, Zou Y, Rasmussen SG, Liu CW, Nygaard R, Rosenbaum DM, et al,. (2010). Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor. Nature 463: 108-112.
5. Bradford MM, (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 7: 248-254.
6. Brede M, Wiesmann F, Jahns R, Hadamek K, Arnolt C, Neubauer S, et al,. (2002). Feedback inhibition of catecholamine release by two different alpha2-adrenoceptor subtypes prevents progression of heart failure. Circulation 106: 2491-2496. (Pubitemid 35278807)
7. Cheng Y, Prusoff WH, (1973). Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108.
8. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, et al,. (2007). High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 318: 1258-1265. (Pubitemid 350172884)
9. Cockcroft V, Frang H, Pihlavisto M, Marjamäki A, Scheinin M, (2000). Ligand recognition of serine-cysteine amino acid exchanges in transmembrane domain 5 of alpha2-adrenergic receptors by UK 14,304. J Neurochem 74: 1705-1710. (Pubitemid 30163993)
10. 3H]RX821002 to the alpha-2 adrenergic receptor subtypes. J Pharmacol Exp Ther 278: 1215-1227. (Pubitemid 27166972)
11. Eason MG, Jacinto MT, Theiss CT, Liggett SB, (1994). The palmitoylated cysteine of the cytoplasmic tail of alpha 2A-adrenergic receptors confers subtype-specific agonist-promoted downregulation. Proc Natl Acad Sci USA 91: 11178-11182.
12. Frang H, Cockcroft V, Karskela T, Scheinin M, Marjamäki A, (2001). Phenoxybenzamine binding reveals the helical orientation of the third transmembrane domain of adrenergic receptors. J Biol Chem 276: 31279-31284. (Pubitemid 37384998)
13. 3H]RX821002 as radioligands. Biochim Biophys Acta 1266: 207-214.
14. Hanson MA, Cherezov V, Griffith MT, Roth CB, Jaakola VP, Chien EY, et al,. (2008). A specific cholesterol binding site is established by the 2.8 Å structure of the human β2-adrenergic receptor. Structure 16: 897-905. (Pubitemid 351778384)
15. Hein L, Kobilka BK, (1995). Adrenergic receptor signal transduction and regulation. Neuropharmacology 34: 357-366.
16. Hein L, Altman JD, Kobilka BK, (1999). Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission. Nature 402: 181-184.
17. Jaakola VP, Griffith MT, Hanson MA, Cherezov V, Hien EY, Lane JR, et al,. (2008). The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 322: 1211-1217.
18. Johnson MS, Overington JP, (1993). A structural basis for sequence comparisons. An evaluation of scoring methodologies. J Mol Biol 233: 716-738. (Pubitemid 23314782)
19. Jones G, Willett P, Glen RC, Leach AR, Taylor R, (1997). Development and validation of a genetic algorithm for flexible docking. J Mol Biol 267: 727-748. (Pubitemid 27170693)
20. Laurila JM, Xhaard H, Ruuskanen JO, Rantanen MJ, Karlsson HK, Johnson MS, et al,. (2007). The second extracellular loop of alpha2A-adrenoceptors contributes to the binding of yohimbine analogues. Br J Pharmacol 151: 1293-1304. (Pubitemid 47255899)
21. Link RE, Desai K, Hein L, Stevens ME, Chruscinski A, Bernstein D, et al,. (1996). Cardiovascular regulation in mice lacking alpha2-adrenergic receptor subtypes b and c. Science 273: 803-805. (Pubitemid 26271527)
22. MacDonald E, Scheinin M, (1995). Distribution and pharmacology of alpha2-adrenoceptors in the central nervous system. J Physiol Pharmacol 46: 241-258.
23. MacDonald E, Kobilka BK, Scheinin M, (1997). Gene targeting-homing in on alpha2-adrenoceptor-subtype function. Trends Pharmacol Sci 18: 211-219. (Pubitemid 27283651)
24. MacMillan LB, Hein L, Smith MS, Piascik MT, Limbird LE, (1996). Central hypotensive effects of the alpha2a-adrenergic receptor subtype. Science 273: 801-803. (Pubitemid 26271526)
25. Mansouri J, Panigrahy A, Assmann SF, Kinney HC, (2001). Distribution of alpha2-adrenergic receptor binding in the developing human brain stem. Pediatr Dev Pathol 4: 222-236. (Pubitemid 32423821)
26. Marjamäki A, Frang H, Pihlavisto M, Hoffrén AM, Salminen T, Johnson MS, et al,. (1999). Chloroethylclonidine and 2-aminoethyl methanethiosulfonate recognize two different conformations of the human alpha(2A)-adrenergic receptor. J Biol Chem 274: 21867-21872.
27. Michino M, Abola E, GPCR Dock 2008 participants, Brooks CL 3rd, Dixon JS, Moult J, Stevens RC, (2009). Community-wide assessment of GPCR structure modelling and ligand docking: GPCR Dock 2008. Nat Rev Drug Discov 8: 455-463.
28. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, et al,. (2000). Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289: 739-745. (Pubitemid 30650186)
29. Peltonen JM, Nyrönen T, Wurster S, Pihlavisto M, Hoffrén AM, Marjamäki A, et al,. (2003). Molecular mechanisms of ligand-receptor interactions in transmembrane domain V of the alpha2A-adrenoceptor. Br J Pharmacol 140: 347-358. (Pubitemid 37249195)
30. Pohjanoksa K, Jansson CC, Luomala K, Marjamäki A, Savola JM, Scheinin M, (1997). Alpha2-adrenoceptor regulation of adenylyl cyclase in CHO cells: Dependence on receptor density, receptor subtype and current activity of adenylyl cyclase. Eur J Pharmacol 335: 53-63. (Pubitemid 27450469)
31. Porter JE, Hwa J, Perez DM, (1996). Activation of the alpha1b-adrenergic receptor is initiated by disruption of an interhelical salt bridge constraint. J Biol Chem 271: 28318-28323. (Pubitemid 26374647)
32. Prusis P, Uhlén S, Petrovska R, Lapinsh M, Wikberg JE, (2006). Prediction of indirect interactions in proteins. BMC Bioinformatics 7: 167.
33. Robinson PR, Cohen GB, Zhukovsky EA, Oprian DD, (1992). Constitutively active mutants of rhodopsin. Neuron 4: 719-725.
34. Rosenbaum DM, Cherezov V, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, et al,. (2007). GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science 318: 1266-1273. (Pubitemid 350172885)
35. Ruffolo RR, Hieble JP, (1994). Alpha-adrenoceptors. Pharmacol Ther 61: 1-64. (Pubitemid 2088932)
36. Ruuskanen JO, Xhaard H, Marjamäki A, Salaneck E, Salminen T, Yan YL, et al,. (2004). Identification of duplicated fourth alpha2-adrenergic receptor subtype by cloning and mapping of five receptor genes in zebrafish. Mol Biol Evol 21: 14-28. (Pubitemid 38233514)
37. Ruuskanen JO, Laurila J, Xhaard H, Rantanen VV, Vuoriluoto K, Wurster S, et al,. (2005). Conserved structural, pharmacological and functional properties among the three human and five zebrafish alpha 2-adrenoceptors. Br J Pharmacol 144: 165-177. (Pubitemid 40216115)
38. Sali A, Blundell TL, (1993). Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234: 779-815. (Pubitemid 24007801)
39. Saunders C, Limbird LE, (1999). Localization and trafficking of alpha2-adrenergic receptor subtypes in cells and tissues. Pharmacol Ther 84: 193-205. (Pubitemid 29488551)
40. Scheinin M, Lomasney JW, Hayden-Hixson DM, Schambra UB, Caron MG, Lefkowitz RJ, et al,. (1994). Distribution of alpha2-adrenergic receptor subtype gene expression in rat brain. Brain Res Mol Brain Res 21: 133-149.
41. Shi L, Simpson MM, Ballesteros JA, Javitch JA, (2001). The first transmembrane segment of the dopamine D2 receptor: Accessibility in the binding-site crevice and position in the transmembrane bundle. Biochemistry 40: 12339-12348. (Pubitemid 32959756)
42. Strader CD, Sigal IS, Register RB, Candelore MR, Rands E, Dixon RA, (1987). Identification of residues required for ligand binding to the beta-adrenergic receptor. Proc Natl Acad Sci USA 84: 4384-4388. (Pubitemid 17097839)
43. Strader CD, Candelore MR, Hill WS, Sigal IS, Dixon RA, (1989). Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor. J Biol Chem 264: 13572-13578. (Pubitemid 19198437)
44. Strasser A, Striegl B, Wittmann HJ, Seifert R, (2008a). Pharmacological profile of histaprodifens at four recombinant histamine H1 receptor species isoforms. J Pharmacol Exp Ther 324: 60-71. (Pubitemid 350294157)
45. Strasser A, Wittmann HJ, Seifert R, (2008b). Ligand-specific contribution of the N terminus and E2-loop to pharmacological properties of the histamine H1-receptor. J Pharmacol Exp Ther 326: 783-791.
46. Surgand JS, Rodrigo J, Kellenberger E, Rognan D, (2006). A chemogenomic analysis of the transmembrane binding cavity of human G-protein-coupled receptors. Proteins 62: 509-538. (Pubitemid 43054370)
47. Suryanarayana S, Daunt DA, Von Zastrow M, Kobilka BK, (1991). A point mutation in the seventh hydrophobic domain of the alpha 2-adrenergic receptor increases its affinity for a family of beta receptor antagonists. J Biol Chem 266: 15488-15492. (Pubitemid 21907674)
48. 3H]RS79948-197 binding to human, rat, guinea pig and pig alpha2A-, alpha2B- and alpha2C-adrenoceptors. Comparison with MK912, RX821002, rauwolscine and yohimbine. Eur J Pharmacol 343: 93-101.
49. Vainio MJ, Puranen JS, Johnson MS, (2009). ShaEP: molecular overlay based on shape and electrostatic potential. J Chem Inf Model 49: 492-502.
50. Wang CD, Buck MA, Fraser CM, (1991). Site-directed mutagenesis of alpha2A-adrenergic receptors: Identification of amino acids involved in ligand binding and receptor activation by agonists. Mol Pharmacol 40: 168-179.
51. Warne T, Serrano-Vega MJ, Baker JG, Moukhametzianov R, Edwards PC, Henderson R, et al,. (2008). Structure of a beta1-adrenergic G-protein-coupled receptor. Nature 454: 486-491.
52. Weis WI, Kobilka BK, (2008). Structural insights into G-protein-coupled receptor activation. Curr Opin Struct Biol 18: 734-740.
53. Wittmann HJ, Seifert R, Strasser A, (2009). Contribution of binding enthalpy and entropy to affinity of antagonist and agonist binding at human and guinea pig histamine H(1)-receptor. Mol Pharmacol 76: 25-37.
54. Wurch T, Colpaert FC, Pauwels PJ, (1998). Chimeric receptor analysis of the ketanserin binding site in the human 5-hydroxytryptamine1D receptor: importance of the second extracellular loop and fifth transmembrane domain in antagonist binding. Mol Pharmacol 56: 1088-1096. (Pubitemid 29002053)
55. Xhaard H, Nyrönen T, Rantanen VV, Ruuskanen JO, Laurila J, Salminen T, et al,. (2005). Model structures of alpha-2 adrenoceptors in complex with automatically docked antagonist ligands raise the possibility of interactions dissimilar from agonist ligands. J Struct Biol 150: 126-143. (Pubitemid 40615738)
56. Xhaard H, Rantanen VV, Nyrönen T, Johnson MS, (2006). Molecular evolution of adrenoceptors and dopamine receptors: Implications for the binding of catecholamines. J Med Chem 49: 1706-1719. (Pubitemid 43376514)
57. Zhao MM, Hwa J, Perez DM, (1996). Identification of critical extracellular loop residues involved in alpha 1-adrenergic receptor subtype-selective antagonist binding. Mol Pharmacol 50: 1118-1126. (Pubitemid 26384850)